KALA BIO, INC. Other Comprehensive Income (Loss), Net of Tax
KALA BIO, INC. (KALA) reported Other Comprehensive Income (Loss), Net of Tax of -$8.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2024-11-12
- KALA BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was -$8.00K, a 900.00% decline year-over-year.
- KALA BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was $9.00K, a 800.00% increase year-over-year.
- KALA BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was $1.00K.
- KALA BIO, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was $1.00K.
- KALA BIO, INC. other comprehensive income (loss), net of tax for fiscal 2021 was -$4.00K, a 200.00% decline from fiscal 2020.
- KALA BIO, INC. other comprehensive income (loss), net of tax for fiscal 2020 was $4.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$8.00K 10-Q · filed 2024-11-12 | $1.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $9.00K 10-Q · filed 2024-08-06 | $9.00K 10-Q · filed 2024-08-06 | ||
| 2022-09-30 | $1.00K 10-Q · filed 2023-11-13 | $2.00K derived: sum of 2 quarters · filed 2023-11-13 | $0.00 derived: sum of 3 quarters · filed 2023-11-13 | $0.00 derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.00K 10-Q · filed 2023-08-04 | -$1.00K 10-Q · filed 2023-08-04 | -$1.00K derived: sum of 3 quarters · filed 2023-08-04 | -$1.00K derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | -$2.00K 10-Q · filed 2023-05-09 | -$2.00K derived: sum of 2 quarters · filed 2023-05-09 | -$2.00K derived: sum of 3 quarters · filed 2023-05-09 | -$5.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $0.00 derived: sum of 2 quarters · filed 2023-03-03 | -$3.00K derived: sum of 3 quarters · filed 2023-03-03 | -$4.00K 10-K · filed 2023-03-03 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$3.00K derived: sum of 2 quarters · filed 2022-11-08 | -$4.00K 10-Q · filed 2022-11-08 | $3.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$3.00K 10-Q · filed 2022-08-11 | -$4.00K 10-Q · filed 2022-08-11 | $3.00K derived: sum of 3 quarters · filed 2022-08-11 | $17.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$1.00K 10-Q · filed 2022-05-16 | $6.00K derived: sum of 2 quarters · filed 2022-05-16 | $20.00K derived: sum of 3 quarters · filed 2022-05-16 | $37.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $21.00K derived: sum of 2 quarters · filed 2022-03-29 | $38.00K derived: sum of 3 quarters · filed 2022-03-29 | $4.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $14.00K 10-Q · filed 2021-11-15 | $31.00K derived: sum of 2 quarters · filed 2021-11-15 | -$3.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $17.00K 10-Q · filed 2021-08-05 | $17.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |